Youming Long1, Yangbo Zheng1, Fulan Shan1, Mengyu Chen1, Yongxiang Fan1, Bin Zhang1, Cong Gao2, Qingchun Gao1, Ning Yang3. 1. Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Institute of Neuroscience and the Second Affiliated Hospital of GuangZhou Medical University, 250# Changgang East Road, GuangZhou, 510260 Guangdong Province, China; Department of Neurology, The Second Affiliated Hospital of GuangZhou Medical University, 250# Changgang East Road, GuangZhou, 510260 Guangdong Province, China. 2. Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Institute of Neuroscience and the Second Affiliated Hospital of GuangZhou Medical University, 250# Changgang East Road, GuangZhou, 510260 Guangdong Province, China; Department of Neurology, The Second Affiliated Hospital of GuangZhou Medical University, 250# Changgang East Road, GuangZhou, 510260 Guangdong Province, China. Electronic address: smilegaocong@126.com. 3. Department of Neurology, The Fifth Affiliated Hospital of GuangZhou Medical University, 621# Gangwan Road, GuangZhou, 510700 Guangdong Province, China.
Abstract
OBJECTIVE: To develop a cell-based assay (CBA) to detect aquaporin 1 (AQP1) antibodies and determine sensitivity/specificity in patients with neuromyelitis optica (NMO) spectrum disorders. METHODS: A HEK-293T transfected cell model expressing AQP1 was established and detected to be serum AQP1 antibodies. RESULTS: AQP1 antibodies were present in 73/98 (74.5%) AQP4 antibody-positive patients. Some AQP4 antibody-negative patients were also AQP1 antibody-positive. Test sensitivity was 74.5% in 98 AQP4 antibody-positive patients. Test specificity was 79.6% in 67 multiple sclerosis (MS) patients and 31 controls. CONCLUSION: A sensitive and simple CBA was developed to detect serum AQP1 antibodies. AQP1 antibodies were mainly present in NMO and its high-risk syndrome, but also in some MS patients.
OBJECTIVE: To develop a cell-based assay (CBA) to detect aquaporin 1 (AQP1) antibodies and determine sensitivity/specificity in patients with neuromyelitis optica (NMO) spectrum disorders. METHODS: A HEK-293T transfected cell model expressing AQP1 was established and detected to be serum AQP1 antibodies. RESULTS:AQP1 antibodies were present in 73/98 (74.5%) AQP4 antibody-positive patients. Some AQP4 antibody-negative patients were also AQP1 antibody-positive. Test sensitivity was 74.5% in 98 AQP4 antibody-positive patients. Test specificity was 79.6% in 67 multiple sclerosis (MS) patients and 31 controls. CONCLUSION: A sensitive and simple CBA was developed to detect serum AQP1 antibodies. AQP1 antibodies were mainly present in NMO and its high-risk syndrome, but also in some MSpatients.
Authors: Imke Metz; Tim Beißbarth; David Ellenberger; Florence Pache; Lidia Stork; Marius Ringelstein; Orhan Aktas; Sven Jarius; Brigitte Wildemann; Hassan Dihazi; Tim Friede; Wolfgang Brück; Klemens Ruprecht; Friedemann Paul Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-02-02
Authors: Ismael Sánchez Gomar; María Díaz Sánchez; Antonio José Uclés Sánchez; José Luis Casado Chocán; Nela Suárez-Luna; Reposo Ramírez-Lorca; Javier Villadiego; Juan José Toledo-Aral; Miriam Echevarría Journal: Int J Mol Sci Date: 2016-07-23 Impact factor: 5.923
Authors: Michal K Oklinski; Mariusz T Skowronski; Agnieszka Skowronska; Michael Rützler; Kirsten Nørgaard; John D Nieland; Tae-Hwan Kwon; Søren Nielsen Journal: Int J Mol Sci Date: 2016-12-07 Impact factor: 5.923
Authors: Lidia Stork; David Ellenberger; Klemens Ruprecht; Markus Reindl; Tim Beißbarth; Tim Friede; Tania Kümpfel; Lisa A Gerdes; Mareike Gloth; Thomas Liman; Friedemann Paul; Wolfgang Brück; Imke Metz Journal: Acta Neuropathol Date: 2020-01-16 Impact factor: 17.088